IP Offerings Logo


Patent MarketPlace: Pharmaceutical Patents for Sale

Topical Treatment for Chronic Wounds (Medergo): U.S. Patent and Patent Application

Chronic wounds – injuries that take longer than they should to heal – are an increasing problem in medicine, especially for older Americans. And the most common reason that wounds do not heal is poor circulation – the wound is not getting sufficient blood flow – so it is not receiving the nutrients and oxygen it needs to heal. And when a chronic wound becomes a catastrophic wound, such unattractive options such as amputation must be considered!

This portfolio covers five different formulations for a prescription, topical, transdermal treatment for a multitude of wounds. Formulations include a calcium channel blocker, alpha-adrenergic antagonist, direct vasodilator, phosphodiesterase-type five inhibitor or hemorrheologic agent, along with dermal penetrating agents and topical stimulating agents. Use of these ingredients in a transdermal formulation results in dramatically increased blood flow that enables the body to heal the wound more efficiently. Since all of the ingredients in the formula are already safe and proven FDA-approved chemicals on their own, a topical, transdermal treatment based on this portfolio should not require a lengthy FDA-approval process.

U.S. Patent No. 10,143,694 for “Advanced formulations and therapies for treating hard-to-heal wounds” covers two formulations, and U.S. Patent Application 20190099426 covers three additional formulations. This portfolio will enable its acquirer to offer a totally safe, very affordable, and highly effective wound-healing topical medication.

Canola-Based Skin Whitener (KGK): International Patent Portfolio

Women of all ethnicities around the world have used skin whiteners for decades to reduce over-pigmentation and address skin conditions such as aging spots, liver spots, freckles, acne scars and melasma, and to even out the color of their skin, giving them a younger look. One of the most common skin whiteners is hydroquinone, but hydroquinone comes with several side effects - skin irritation and sensitization, burning, stinging, dermatitis, dryness, redness and inflammation. What is needed in the marketplace is an effective and affordable skin whitener made from natural ingredients so it has far fewer side effects.

That product now exists and it is covered by this portfolio. Using 100% natural canola extracts, this portfolio creates a next-generation skin whitener that is effective, but with NO side effects!

Patent Portfolio

The acquirer of this portfolio will be able to introduce a skin whitening product line that is affordable and effective, but with NO side effects so it can be used on a daily basis and incorporated into cosmetic products such as foundation.

Blood Glucose Reduction (KGK): International Portfolio

Metabolic Syndrome is a condition that affects over 20% of adult Americans, and three million new cases are diagnosed each year. Metabolic Syndrome includes high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. Metabolic Syndrome significantly increases a person's risk for heart attack and stroke. If we could treat Americans with Metabolic Syndrome when it is first diagnosed, we would prevent millions – quite literally millions – of heart attacks and strokes each year!

This portfolio takes on that challenge head-on! It creates a medication consisting of limonoids (extracts from sweet or sour-scented citrus fruits), flavonoids (fruit and vegetable extracts that contain 15 carbon atoms and are soluble in water) and tocotrienols (vegetable extracts with unsaturated isoprenoid side chains with three carbon-carbon double bonds) that provides anti-diabetic and antihyperlipidemic benefits to diabetic subjects who are currently on medication but not meeting their physician’s target levels for blood glucose, Hemoglobin A1C, blood pressure and total cholesterol.

Patent Portfolio

One of the primary benefits of the composition created by this portfolio is that none of the ingredients are synthesized but are widely used natural substances. This portfolio would be a strategic acquisition for any pharmaceutical or nutritional supplement company seeking to provide a new and effective treatment for reducing blood sugar levels.

Next-Generation NSAID (Kazan): International Patent Portfolio

Global annual sales of nonsteroidal anti-inflammatory drugs (NSAIDs) are estimated to be over $12 billion. In the U.S. alone, over 10 million prescriptions are written each year for Naproxen and over 25 million for Ibuprofen. Naproxen is sold under various over-the-counter formulations – Aleve® being the most popular. Naproxen is an NSAID that treats pain from inflammatory diseases such as rheumatoid arthritis and joint disease as well as menstrual cramps, fever and other maladies. While Naproxen and Ibuprofen are popular and widely used, they come with numerous known side effects that include dizziness, headaches, bruising, allergic reactions, heartburn and – most often – stomach pain. The use of Naproxen and Ibuprofen is also known to increase the risk of heart disease, gastrointestinal bleeding and stomach ulcers.

This international portfolio is directed to a next-generation NSAID and has been shown in pre-clinical studies to be more effective than Naproxen and Ibuprofen as an anti-inflammatory agent, analgesic and fever reducer while having significantly less side effects than either Naproxen or Ibuprofen and being approximately 40 times less gastrotoxic than Naproxen and approximately seven times less gastrotoxic than Ibuprofen. Since this new formulation uses currently approved ingredients (Vitamin B6 and Naproxen), testing and approval for introduction of a new drug based on this formulation should be relatively routine and expeditious.

Patent Portfolio

This portfolio would be a strategic acquisition for any pharmaceutical company seeking long-term dominance in the global NSAID market.

Aleve is a registered trademark of Bayer AG.

Colon Cancer Screening (Lee): Portfolio of Four U.S. Patents

Despite the popularity and increased use of colonoscopies, 50,000 people will die in the U.S. from colon cancer this year. This portfolio covers a technology that replaces the traditional colonoscopy with a test that effectively detects the earliest stage of colon cancer, and also detects large and still-benign polyps. Unlike a colonoscopy, this test does not require bowel preparation or anesthesia. The technology covered by this portfolio – which is supported by several published studies – detects highly altered mRNA activity from a simple rectal smear.

Patent No.Title
8,883,440Method to predict or diagnose a gastrointestinal disorder or disease
9,353,420Method to predict or diagnose a gastrointestinal disorder or disease
10,011,879Method to predict or diagnose a gastrointestinal disorder or disease
10,400,284Method to predict or diagnose a gastrointestinal disorder or disease

The company that acquires this portfolio will be able to offer an affordable test that accurately and reliably detects the earliest instance of colon cancer without the cost, time and inconvenience of a colonoscopy. The Prospectus includes the published studies that support this patented technology.

New Technology for Producing Collagen (Malinin): U.S. Patent No. 9,737,590

Collagen is used in cosmetic surgery, wound care, filling tissue voids and for regeneration of damaged structure. This patent describes a method of producing pure collagen from source material of various tissues – both human and animal – that can be used for a variety of therapeutic and cosmetic applications. The technology covered by this patent enables collagen fibers to be separated from freeze-dried tissues by a magnetic field in a liquid medium. This method induces collagen fibers to self-assemble and produce gels, paste membranes and various other configurations. An additional benefit is that the patented process does not depend on harsh chemical treatment such as hydrolysis or harsh physical treatment. This technology is superior to currently available techniques because it can utilize human tissues as source material and because it can produce collagen without cross-linking.

U.S. Patent No. 9,737,590 for "Self-assembly of collagen fibers from dermis, fascia and tendon for tissue augmentation and coverage of wounds and burns" would be a strategic acquisition for any biomedical or pharmaceutical company that is currently producing regeneration products as it would give this company a critical competitive advantage by enabling it to offer a new and unique variety of collagen products.

Alternate Treatment for Colon Cancer (System C): International Patent Portfolio

Until just recently, all cancer treatments were either chemotherapy or radiation. This portfolio covers a non-chemotherapy treatment for colon cancer that uses the cognitive ability of the brain to fundamentally cure a disease. The inventor – a physician – tested the concept on his patients with good results. The patents in the portfolio call for pre-surgery administration over a period of days of haloperidol, ascorbic acid, calcium pantothenate, and a solution of maltose, potassium chloride, magnesium chloride, potassium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, magnesium chloride hexahydrate, anhydrous sodium acetate and maltose monohydrate. That is followed with Luvox and sodium ferrous citrate if the patient is anemic. This treatment, pre-surgery, enhances the cognitive ability of the brain to guide the body’s organs and systems to cure itself from cancer.

Patent Portfolio

The PCT Application is currently inactive, but it could re re-activated and used to secure additional, national patents. Most importantly, the specific medications that comprise the total treatment have either no or very minor side effects, so the prescribed treatment is a Low Risk/High Reward proposition! This portfolio would be a critical acquisition for any pharmaceutical company!


Treatment of Cerebral Palsy and Multiple Sclerosis (Gilrose Pharmaceuticals) Twelve U.S. Patents, Two PCT Patent Applications and One U.S. Patent Application

This portfolio covers a new application for an existing drug for the treatment of brain disorders known as Pre-Frontal Processing Disorder (PFD). This condition is defined by the inability of the pre-frontal cortex to integrate sensory input with motor output. This drug can be used to treat Cerebral Palsy, Multiple Sclerosis, and Autism-spectrum sufferers with Speech Apraxia and Gait Disorder.

Patent No.Title
8,883,815Treatment for cerebral palsy impaired speech in children
9,089,563Method of treating apraxia of speech on children
9,155,502Treatment for cerebral palsy impaired speech in children
9,161,718Treatment for cerebral palsy impaired speech in children
9,220,712Pharmaceutical intervention and method for treating an apraxia of speech in children
9,307,942Treatment for cerebral palsy gait impairment
9,333,198Treatment for cerebral palsy gait impairment
9,375,421Pharmaceutical intervention for treating an apraxia of speech in children
9,408,838Treatment for cerebral palsy gait impairment
9,682,073Pre-frontal cortex processing disorder gait and limb impairments treatment
10,085,414Pre-frontal cortex processing disorder gait and limb impairments treatment
10,420,318Pre-frontal cortex processing disorder gait and limb impairments treatment
 
Application No.Title
WO2015061125Treatment of cerebral palsy impaired speech in children
WO2017007577Pre-frontal cortex processing disorder, gait and limb impairment treatment
20190320611Pre-frontal cortex processing disorder gait and limb impairments treatment

The acquirer of this portfolio will have to invest in clinical trials, but it will have a drug it can take to market to treat over 100 million sufferers worldwide, and it can use the PCT Patent Applications to secure patent coverage in over 100 countries for global patent coverage.

Patent Brokerage Prospectus: Contact [email protected] to receive an analysis of each portfolio that includes:

We offer patents in these technologies: